Business Description
BeOne Medicines Ltd
NAICS : 541714
SIC : 2834
ISIN : US07725L1026
Share Class Description:
ONC: ADRTotal Employee Number:
12,000Compare
Compare
Traded in other countries / regions
ONC.USA06160.Hong Kong688235.ChinaIJ0.GermanyB1ME34.BrazilBGNEN.Mexico IPO Date
2016-02-03Description
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.17 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | 1.27 | |||||
Interest Coverage | 7.53 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.53 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 50.8 | |||||
3-Year Book Growth Rate | -2.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 73.46 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.56 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.51 | |||||
9-Day RSI | 59.88 | |||||
14-Day RSI | 57.98 | |||||
3-1 Month Momentum % | -14.87 | |||||
6-1 Month Momentum % | -21.98 | |||||
12-1 Month Momentum % | 4.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.64 | |||||
Quick Ratio | 3.27 | |||||
Cash Ratio | 2.65 | |||||
Days Inventory | 306.8 | |||||
Days Sales Outstanding | 52.84 | |||||
Days Payable | 218.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.31 | |||||
Operating Margin % | 11.95 | |||||
Net Margin % | 8.94 | |||||
EBITDA Margin % | 15.79 | |||||
FCF Margin % | 19.06 | |||||
OCF Margin % | 22.39 | |||||
ROE % | 12.5 | |||||
ROA % | 7.02 | |||||
ROIC % | 19.03 | |||||
3-Year ROIIC % | 498.32 | |||||
ROC (Joel Greenblatt) % | 41.21 | |||||
ROCE % | 14.37 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 69.63 | |||||
Forward PE Ratio | 45.68 | |||||
PE Ratio without NRI | 29.84 | |||||
Price-to-Owner-Earnings | 75.71 | |||||
PS Ratio | 5.97 | |||||
PB Ratio | 6.97 | |||||
Price-to-Tangible-Book | 7.07 | |||||
Price-to-Free-Cash-Flow | 31.3 | |||||
Price-to-Operating-Cash-Flow | 26.69 | |||||
EV-to-EBIT | 38.28 | |||||
EV-to-Forward-EBIT | 34.88 | |||||
EV-to-EBITDA | 31.94 | |||||
EV-to-Forward-EBITDA | 27.29 | |||||
EV-to-Revenue | 5.04 | |||||
EV-to-Forward-Revenue | 4.54 | |||||
EV-to-FCF | 26.45 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Price-to-Graham-Number | 3.06 | |||||
| Price-to-Net-Current-Asset-Value | 11.83 | |||||
| Price-to-Net-Cash | 33.26 | |||||
Earnings Yield (Greenblatt) % | 2.61 | |||||
FCF Yield % | 3.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeOne Medicines Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,739.192 | ||
| EPS (TTM) ($) | 4.29 | ||
| Beta | 0.5953 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 0.88 | ||
| Volatility % | 36.4 | ||
| 14-Day RSI | 57.98 | ||
| 14-Day ATR ($) | 8.912295 | ||
| 20-Day SMA ($) | 282.758 | ||
| 12-1 Month Momentum % | 4.03 | ||
| 52-Week Range ($) | 249 - 385.22 | ||
| Shares Outstanding (Mil) | 103.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeOne Medicines Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeOne Medicines Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 119 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 26 days | ||
| General meeting for 2026 | 2026-06-11 09:30 | 263.61 (-1.21%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 10:00 | 270.10 (-1.85%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 297.49 (+0.16%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 297.49 (+0.16%) | ||
| Citizens Life Sciences Conference | 2026-03-10 09:35 | 302.29 (+3.17%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 11:20 | 301.12 (+2.95%) |
Show
Entries
BeOne Medicines Ltd Frequently Asked Questions
What is BeOne Medicines Ltd(ONC)'s stock price today?
The current price of ONC is $298.70. The 52 week high of ONC is $385.22 and 52 week low is $249.00.
When is next earnings date of BeOne Medicines Ltd(ONC)?
The next earnings date of BeOne Medicines Ltd(ONC) is 2026-08-06 Est..
Does BeOne Medicines Ltd(ONC) pay dividends? If so, how much?
BeOne Medicines Ltd(ONC) does not pay dividend.
Guru Commentaries on NAS:ONC
No articles.
Press Release
Articles on BeOne Medicines Ltd
Headlines
See More- 1
Jun 11, 2026
Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years
Benzinga • 10:30am
Insider Unloading: JOHN OYLER Sells $1.34M Worth Of BeOne Medicines Shares
Benzinga • 10:02am
Insider Decision: Xiaobin Wu Offloads $399K Worth Of BeOne Medicines Stock
Benzinga • 10:02am
BeOne Medicines President Trades $368K In Company Stock
Benzinga • 10:02am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers